Consolidated Statements of Operations

	Year Ended October 31,
		2002		2001		2000
		(In thousands, except share and per share data)
Revenues:
Oxyglobin	$ 1,988	$ 3,482	$ 3,058
Other	1	7	5
Total revenues	1,989	3,489	3,063
Cost of revenues	7,401	3,665	4,778
Gross profit (loss)	(5,412)	(176)	(1,715)
Operating expenses:
Research and development	25,982	34,609	26,378
Sales and marketing	3,028	2,807	2,463
General and administration	12,235	15,365	9,878
Total operating expenses	41,245	52,781	38,719
Loss from operations	(46,657)	(52,957)	(40,434)
Other income (expense):
Interest income	679	3,609	4,424
Interest expense	(47)	(71)	(68)
Other	242	---	---
Total other income, net	874	3,538	4,356
Net loss	$ (45,783)	$ (49,419)	$ (36,078)
Per share data:
Basic and diluted net loss per common share	$ (1.66)	$ (1.97)	$ (1.51)
Weighted-average shares used in computing basic and       diluted net loss per common share	27,582,301	25,066,132	23,947,251